People · Operator
Named in public records as an officer, director or promoter · active 2018–2023 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Inhibrx, Inc. | — | Biotechnology | Growth/Late | $668.6M | $3.3B | 2018 |
Mark Lappe at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Mark Lappe on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Judith Li | 1 | 8 |
| Kristiina Vuori | 1 | 2 |
| Jon Kayyem | 1 | 2 |
| Jon Faiz Kayyem | 1 | 2 |
| Doug Forsyth | 1 | 2 |
| Kimberly Manhard | 1 | 1 |
| Douglas Forsyth | 1 | 1 |
| Kelly Deck | 1 | 1 |
| Kelly Faiz Deck | 1 | 1 |
| Judith Faiz Li | 1 | 1 |
| Doug Faiz Forsyth | 1 | 1 |
| Margery Faiz Fischbein | 1 | 1 |
| Brendan Eckelman | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.